SALE OF ESSURE Birth Control TO BE DISCONTINUED WORLDWIDE BY END OF 2018

By Amanda Williamson

July 20, 2018

Essure manufacturer, Bayer AG, has announced that it is pulling Essure off the U.S. market by the end of 2018. This announcement follows a series of earlier actions taken by the FDA to address the reports of serious complications associated with Essure use and the filing of over 16,000 lawsuits by women alleging injury caused by Essure. Bayer discontinued the sale of Essure in all countries outside of the United States last year. Essure will now be effectively pulled from markets worldwide.

What is Essure?

Essure is a minimally invasive permanent birth control procedure for women. It is a type of tubal sterilization. A soft, flexible insert is placed into each fallopian tube. The Essure insert is made of materials that include polyester fibers, nickel, titanium, platinum, silver-tin and stainless steel. Over three months after insertion, a barrier forms around the inserts. This barrier, which is made of scar tissue, helps keep sperm from reaching the eggs so pregnancy cannot occur.

Essure was approved by the FDA in 2002. The device was developed by Conceptues Inc. a subsidiary of Bayer AG. Over 750,000 women and their doctors have chosen Essure for permanent birth control.

Reported Complications

Reports of severe complications following the Essure procedure include:

• Additional surgeries, including hysterectomy to remove the device and repair internal organs
• Autoimmune response to the device, including fatigue, rashes, hair loss and weight gain
• Chronic pelvic pain
• Migration of the device or a device component
• Perforation or tear of pelvic organs, including uterus or colon
• Severe migraines and allergic reactions to the device or device components.
• Fetal Death
• Life-threatening Ectopic Pregnancy

FDA Recent Action

• September 2015: The FDA convened a panel of experts to get their input on how we should investigate patient complaints that included abdominal pain, abnormal uterine bleeding and device migration.
• February 2016: The FDA ordered Bayer to conduct a postmarket (522) study to better evaluate the safety profile of the device when used in the real world. The agency announced that it intended to require labeling changes to help patients better understand the potential risks of the device.
• October 2016: The FDA issued the final guidance, “Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization” and in November 2016, the FDA approved updated labeling for Essure consistent with the guidance that added a boxed warning and a Patient Decision Checklist.
• February 2018: FDA officials met with women implanted with Essure and patient advocates to listen to their concerns and experiences with the device.
• March 2018: The FDA reported on a rise in new medical device reports submitted to the agency’s public database in 2017 with more than 90 percent of the reports involving potential device removal.
• April 2018: In order to address concerns that not every patient was receiving adequate risk information, the FDA restricted the sale and distribution of the Essure device.

Contact Us

If you or a loved one has experienced complications after implantation of Essure, please contact us to discuss your options. Even if you feel you are not ready to file a suit, consult one of our qualified lawyers as soon as possible so that you will know your options. We do not charge any fees upfront. In fact, we will only charge attorney’s fees if we obtain a financial settlement for you. If you don’t win, we won’t get paid a legal fee. Call or email us today for your free case evaluation: 1.800.241.9779, Amanda Williamson, or Bill Bross.

 

The post SALE OF ESSURE Birth Control TO BE DISCONTINUED WORLDWIDE BY END OF 2018 appeared first on .